AZD8186

Ligand id: 8527

Name: AZD8186

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 75.02
Molecular weight 457.18
XLogP 4.78
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
AZD8186 in combination with the anti-androgenic drug abiraterone, is being evaluated in Phase 1 clinical trial as a potential treatment for prostate cancer. The two compounds block complementary molecular pathways in prostate cancer, providing synergistic activity. A second Phase 1 study is determining efficacy of AZD8186 plus docetaxel in advanced breast cancer. Click here to link to ClinicalTrials.gov's full list of AZD8186 trials.